Beta-lactam antibiotics;Bêtalactamines

EMC - Maladies Infectieuses

Volumn 1, Issue 3, 2004, Pages 129-202

  Cavallo, J D ^a   Fabre, R ^a   Jehl, F ^b   Rapp, C ^a   Garrabe E ^a  

^a SERVICE D ENDOCRINOLOGIE   (France)

^b Laboratoire de Bactériologie   (France)

Author keywords

Beta lactam antibiotics; Beta lactam pharmacodynamics; Beta lactam pharmacokinetics; Beta lactam resistance

Indexed keywords

EID: 25844494864     PISSN: 1638623X     EISSN: 1638623X     Source Type: Journal    
DOI: 10.1016/j.emcmi.2004.03.003     Document Type: Short Survey

References (149)

1. Agence française de sécurité sanitaire des produits de santé. Sinusite aiguë de l'adulte. Méd Mal Infect 2001;31(suppl):493S-507S.
2. Agence française de sécurité sanitaire des produits de santé. Exacerbations de bronchite chronique. Méd Mol Infect 2001;31(suppl):552S-578S.
3. Agence française de sécurité sanitaire des produits de santé. Otite moyenne aiguë. Méd Mal Infect 2001;31(suppl):579S-600S.
4. Agence française de sécurité sanitaire des produits de santé. Prescription des antibiotiques en odontologie et stomatologie. Méd Mal Infect 2002;32:125-160.
5. Agence française de sécurité sanitaire des produits de santé. Antibiothérapie par voie générale en pratique courante: angine, recommandations. Letttre Infect 2003;18:3-6.
6. Alcaide F, Linares J, Pallares R, Carratala J, Benitez MA, Gudiol F, et al. In vitro activities of 22 β-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 1995;39:2243-2247.
7. Altemeier WA, Culbertson WR, Sherman R, et al. Critical reevaluation of antibiotic therapy in surgery. JAMA 1955;157:305-309.
8. Ambler RP. The structure of β-lactamases. Philos Trans R Soc London Ser B 1980;289:321-331.
9. Antignac A, Ducos-Galand M, Guiyoule A, Pires R, Alonso JM, Taha MK. Neisseria meningitidis strains isolated from invasive infections in France (1999-2002): phenotypes and antibiotic susceptibility patterns. Clin Infect Dis 2003;37:912-920.
10. Antignac A, Kriz P, Tzanakaki G, Alonso JM, Taha MK. Polymorphism of Neisseria meningitidis penA gene associated with reduced susceptibility to penicillin. J Antimicrob Chemother 2001;47:285-296.
11. Bedos JP, Régnier B. Céphalosporines orales. In: Carbon C, Régnier B, Saimot G, Vildé JL, Yeni P, editors. Médicaments anti-infectieux. Paris: Flammarion Médecine-Sciences; 1994. p. 85-101.
12. Berger-Bacchi B, Rohrer S. Factors influencing methicillin-resistance in staphylococci. Arch Microbiol 2002;178:165-171.
13. Bergeron MG. Pénèmes, carbapénèmes et monobactames. In: Carbon C, Régnier B, Saimot G, Vildé JL, Yeni P, editors. Médicaments anti-infectieux. Paris: Flammarion Médecine-Sciences; 1994.
14. Bergogne-Bérézin E. Relation structure-activité de la ceftazidime, conséquences sur le spectre bactérien. Presse Méd 1988;17:1879-1882.
15. Bernard E, Breihl D, Bru JP, Chiche D, Dujardin I, Garaffo R, et al. Is there a rational for the continuous infusion of cefepime? A multidisciplinary approach. Clin Microbiol Infect 2003;9:339-348.
16. Bismuth R, Leclercq R. Staphylococcus aureus et antibiotiques. In: Freney J, Renaud F, Hansen W, Bollet C, editors. Précis de bactériologie clinique. Paris: Éditions ESKA-Alexandre Lacassagne; 2000. p. 611-618.
17. Bonnet R, Machardin H, Chanal C, Sirot D, Labia R, de Champs C, et al. Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis. Antimicrob Agents Chemother 2002;46:2004-2006.
18. Bosi C, Regli AD, Bornet C, Mallea M, Pages JM, Bollet C. Most Enterobacter aerogenes strains in France belong to a prevalent clone. J Clin Microbiol 1999;37:2165-2169.
19. Bowler LD, Zhang QY, Riou JY, Spratt BG. Interspecies recombination between the penA genes of Neisseria meningitidis and commensal Neisseria species during the emergence of penicillin-resistance in N. meningitidis: natural events and laboratory simulation. J Bacteriol 1994;176:333-337.
20. st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-951.
21. Breuil J, Casin I, Hanaut-Bercot B, Dublanchet A, Collatz E. Bull Epidémiol Hebd 2001;43:203-205 et le Collège de bactériologie, virologie et hygiène des hôpitaux.
22. Bryskier A. Pénicillines. In: Bryskier A, editor. Antibiotiques, agents antibactériens et antifongiques. Paris: Ellipse édition; 1999. p. 157-224.
23. Bryskier A. Carbapénèmes. In: Bryskier A, editor. Antibiotiques, agents antibactériens et antifongiques. Paris: Ellipse édition; 1999. p. 305-347.
24. Bryskier A. Perfecting the ring and extending the antibacterial spectrum: "the multiple generations". Clin Microbiol Infect 2000;6(suppl3):13S-21S.
25. Bryskier A, Aszodi J. Céphèmes à usage parentéral. In: Bryskier A, editor. Antibiotiques, agents antibactériens et antifongiques. Paris: Ellipse édition; 1999. p. 225-285.
26. Bush K. Metallo-β-lactamases: a class apart. Clin Infect Dis 1998;27(suppl1):48S-53S.
27. Bush K. New β-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001;32:1085-1089.
28. Bush K, Jacoby GA, Meideros AA. A functional classification scheme for β-lactamase and its correlation with molecular structures. Antimicrob Agents Chemother 1995;39:1211-1233.
29. Casin I, Breuil J, Brisabois A, Moury F, Grimont F, Collatz Z. Multidrug-resistant human and animal Salmonella typhimurium isolates in France belongs predominantly to a DT104 clone with the chromosome and integron-encoded β-lactamase PSE-1. J Infect Dis 1999;179:1173-1182.
30. Cavallo JD, Plesiat P, Couetdic G, Leblanc F, Fabre R. Mechanisms of β-lactam resistance in Pseudomonas aeruginosa: prevalence of OprM-overproducing strains in a french multicentre study (1997). J Antimicrob Chemother 2002;50:1039-1044.
31. Cavallo JD, Ramisse F, Girardet M, Vaissaire J, Mock M, Hernandez E. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob Agents Chemother 2002;46:2307-2309.
32. Chaïbi EB, Sirot D, Paul G, Labia R. Inhibitor-resistant TEMβ-lactamases: phenotypic, genetic and biochemical charasteristics. J Antimicrob Chemother 1999;43:447-458.
33. Chambers HF. Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J Infect Dis 1999;179(suppl2):S353-S359.
34. Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997;10:781-791.
35. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-182.
36. Chardon H, Varon E, Bensaid, Bellon O, Lagier E, Gutmann L. Epidémiologie de la résistance du pneumocoque aux antibiotiques. Méd Mal Infect 2002;32(suppl1):21-31.
37. Charrel RN, Pagès JM, De Micco, et al. Prevalence of outer membrane porin alteration in β-lactam-antibiotic-resistant Enterobacter aerogenes. Antimicrob Agents Chemother 1996;40:2854-2858.
38. Chidiac C, Mouton Y. Aminopénicillines, amidinopé nicillines. In: Carbon C, Régnier B, Saimot G, Vildé JL, Yeni P, editors. Médicaments anti-infectieux. Paris: Flammarion Médecine-Sciences; 1994. p. 36-42.
39. Choutet P, Besnier JM. Pénicilline G, pénicilline V et pénicilline M. In: Carbon C, Régnier B, Saimot G, Vildé JL, Yeni P, editors. Médicaments anti-infectieux. Paris: Flammarion Médecine-Sciences; 1994. p. 26-35.
40. CMIT. Infections chez le neutropénique. Montmorency 2004;2M2:525-528.
41. Comité de l'antibiogramme de la société française de microbiologie. Report 2003. Int J Antimicrob Agents 2003;21:364-391.
42. Comité technique national des infections nosocomiales. 100 recommandations pour la surveillance et la prévention des infections nosocomiales. Ministère de l'Emploi et de la solidarité. Secrétariat d'État à la Santé et à l'action sociale; 1999.
43. Conférence de consensus. L'antibioprophylaxie en chirurgie. Lettre Infect 1997;12:108-117.
44. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
45. Craig WA, Andes D. Pharmacokinetic and pharmacodynamics of antibiotics in acute otitis media. Pediatr Infect Dis J 1996;15:255-259.
46. Cremieux AC. Inhibiteurs de bêta-lactamases. In: Carbon C, Régnier B, Saimot G, Vildé JL, Yeni P, editors. Médicaments anti-infectieux. Paris: Flammarion Médecine-Sciences; 1994. p. 42-56.
47. Dabernat H. À propos de la sensibilité d'Haemophilus influenzae aux β-lactamines. Presse Med 2001:23-24 (hors-sériel).
48. Dabernat H. Bêta-lactaminés: pénicillines, céphalosporines, carbapénèmes, inhibiteurs de β-lactamase. Antibiothérapie en pratique clinique. Paris: Masson; 1995. p. 105-157.
49. Dabernat H, Delams C, Seguy M, Pelissier R, Faucon G, Bennamani S, et al. Diversity of β-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob Agents Chemother 2002;46:2208-2218.
50. Dabernat H, Plisson-Sauné MA, Delmas C, Seguy M, Faucon G, Pelissier R, et al. Haemophilus influenzae carriage in children attending french day care centers: a molecular epidemiological study. J Clin Microbiol 2003;41:1664-1672.
51. Decazes JM, Thabaut A, Modai J. Carboxypénicillines et uréidopénicillines. In: Carbon C, Régnier B, Saimot G, Vildé JL, Yeni P, editors. Médicaments anti-infectieux. Paris: Flammarion Médecine-Sciences; 1994. p. 56-73.
52. Dubreuil L, Behra-Miellet J. Bactéries anaérobies strictes: taxonomie et bilan de sensibilité aux antimicrobiens. Méd Mal Infect 2000;30(suppl2):77-84.
53. Dubreuil L, Behra-Miellet J. Les Prevotella et leur sensibilité aux β-lactamines. Presse Méd 2001:27-28 (hors-sériel).
54. Fines M, Leclercq R. Entérocoques et antibiotiques. In: Freney J, Renaud F, Hansen W, Bollet C, editors. Précis de bactériologie clinique. Paris: Éditions ESKA-Alexandre Lacassagne; 2000. p. 630-637.
55. Fish DN, Piscitelli SC, Danzinger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapeutics 1995;15:279-291.
56. Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3 051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol 2001;39:3727-3732.
57. Fontana R, Aldegheri M, Ligozzi M, Lopez H, Sucari, Satta G. Overproduction of low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1994;38:1980-1983.
58. Fontana R, Ligozzi M, Cornaglia G. Affinities of cephalosporins for penicillin-binding proteins and their antibacterial activities in the presence of human serum albumin. Clin Microbiol Infect 2000;6(suppl3):82S-83S.
59. Fournier B, Lagrange PH, Philippon A. β-lactamase gene promoters on 71 clinical strains of Klebsiella oxytoca. Antimicrob Agents Chemother 1996;40:460-463.
60. Fournier B, Roy PH. Variability of chromosomally encoded β-lactamases from Klebsiella oxytoca. Antimicrob Agents Chemother 1997;41:1641-1648.
61. Garrabé E, Soullié B, Cavallo JD, Brisou P, Chapalain JC, Coue JC, et al. Sensibilité aux antibiotiques des salmonelles isolées dans les hôpitaux des armées en 1998-1999. Presse Méd 2002;31:787-793.
62. Gemmel CG. Effect of low antibiotic concentration on bacteria: effects on ultrastructure, virulence, and susceptibility to immuno-defenses. In: Lorian V, editor. Antibiotic in laboratory medicine. Baltimore: Williams and Wilkins; 1996. p. 397-452.
63. Gerding DN, Hughes CE, Banberger DM, Foxworth J, Larson TA. Extravascular antimicrobial distribution and the respective blood concentrations in humans. In: Lorian V, editor. Antibiotics in laboratory medicine. Baltimore: Williams and Wilkins; 1996. p. 835-899.
64. Gilbert DN, Moellering RC, Sande MD. The Sandford guide to antimicrobial therapy. 2003. p. 52-53.
65. Gilbert DN, Moellering RC, Sande MD. The Sandford guide to antimicrobial therapy. 2003. p. 60-62.
66. Goldstein FW. Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbiol Infect 2003;8:823-825.
67. Goulet V, Laurent E, Sednaoui P. Les gonococcies en France en 2000: données du réseau RENAGO. In: Institut de Veille Sanitaire, editor. Surveillance nationale des maladies infectieuses 1998-2000. St Maurice: INVS; 2003. p. 63-68.
68. Groupe d'étude de la résistance de Pseudomonas aeruginosa aux bêta-lactamines (GERPB). Évolution de la résistance aux antibiotiques de Pseudomonas aeruginosa en France de 1994 à 1998. Lettre Infect 2000;15:18-23.
69. Hackbarth C, Chambers HF. blal and blaR1 regulate β-lactamase and PLP2A production in methicillin-resistant Staphylococcus aureus. J Bacteriol 1993;37:1144-1149.
70. Hall G, Heimdahl, Nord CE. Bacteremia after oral surgery and antibiotic prophylaxis for endocarditis. Clin Infect Dis 1999;29:1-10.
71. Hanson ND, Sanders ML. Regulation of inducible AmpC beta-lactamase among Enterobacteriaceae. Curr Pharm Des 1999;5:881-894.
72. Hernandez E, Girardet M, Ramisse F, Vidal D, Cavallo JD. Antibiotic susceptibilities of 94 isolates of Yersinia pestis to 24 antimicrobial agents. J Antimicrob Chemother 2003;52:1029-1031.
73. Hiramatsu K, Katayama Y, Yuzawa H, Ito T. Molecular genetics of methicillin-resistant Staphylococcus aureus. Int J Med Microbiol 2002;292:67-74.
74. Holtje JV, Tuomanen EI. The murein hydrolase of Escherichia coli: properties, functions and impact on the course of infections in vivo. J Gen Microbiol 1991;137:441-454.
75. Humeniuk C, Arlet G, Gautier V, Grimont P, Labia R, Philippon A. β-lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types. Antimicrob Agents Chemother 2002;46:3045-3049.
76. Ikaheimo I, Syrjälä H, Karhukorpi J, Schildt R, Koskela M. In vitro antibiotics susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 2000;46:287-290.
77. Jackson JJ, Kropp H. β-lactam antibiotic-induced release of free endotoxin: in vitro comparison or penicillin-binding protein (PBP)2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis 1992;165:1033-1041.
78. Jaffe A, Chabbert YA, Semonin O. Role of porin proteins OmpF and OmpC in the permeation of β-lactam. Antimicrob Agents Chemother 1982;22:942-948.
79. Jarlier V, Nordmann P. Entérobactéries et β-lactamines. In: Freney J, Renaud F, Hansen W, Bollet C, editors. Précis de bactériologie clinique. Paris: Éditions ESKA-Alexandre Lacassagne; 2000. p. 649-665.
80. Jones RN, Baquero F, Privitera G, Inoue M, Wiedermann B. Inducible β-lactamase-mediated resistance to third-generation cephalosporins. Clin Microbiol Infect 1997;3(suppl1):7S-20S.
81. Jorgensen JE. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin Infect Dis 1992;14:1119-1123.
82. Kazmierczak A. Inhibiteurs de bêta-lactamases. In: Bryskier A, editor. Antibiotiques, agents antibactériens et antifongiques. Paris: Ellipse édition; 1999. p. 446-457.
83. Knox JR. Extended-spectrum and inhibitor-resistant TEM-type β-lactamase: mutations, specificity and three-dimensional structure. Antimicrob Agents Chemother 1995;39:2593-2601.
84. Kwon DH, Dore MP, Kim JJ, Kato M, Lee M, Wu JY, et al. High-level β-lactam resistance associated with multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003;47:2169-2178.
85. Lavigne JP, Sotto A, Merle C, Jourdan J, Soussy CJ, Sirot D. Résistance enzymatique d'Escherichia coli aux bêta-lactamines et prévalence en clinique. Pathol Biol 2002;50:388-393.
86. Leclercq R. Enterococci acquire new kinds of resistance. Clin Infect Dis 1997;24(suppl1):80S-84S.
87. Leclercq R. Pneumocoques, autres streptocoques et antibiotiques. In: Freney J, Renaud F, Hansen W, Bollet C, editors. Précis de bactériologie clinique. Paris: Éditions ESKA-Alexandre Lacassagne; 2000. p. 619-629.
88. Lelièvre H, Lina G, Jones ME, Olive C, Forey F, Roussel-Delvallez M, et al. Emergence and spread in French hospitals of methicillin-resistant Staphylococcus aureus with increasing susceptibility to gentamicin and other antibiotics. J Clin Microbiol 1999;37:3452-3457.
89. Le Noc P. Monobactames. In: Bryskier A, editor. Antibiotiques, agents antibactériens et antifongiques. Paris: Ellipse édition; 1999. p. 374-391.
90. Li XZ, Zhang L, Poole K. Interplay between the MexA-MexB-OprM multidrug efflux systems and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother 2000;45:433-436.
91. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-584.
92. Livermore D, Williams JD. β-lactams: mode of action and mechanisms of bacterial resistance. In: Lorian V, editor. Antibiotics in laboratory medicine. Baltimore: Williams and Wilkins; 1996. p. 502-578.
93. MacDougall LK, Thornsberry C. The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins. J Clin Microbiol 1986;90:832-839.
94. Malouin F, Bryan LE. Modification of penicillin-binding proteins as mechamisms of β-lactam resistance. Antimicrob Agents Chemother 1986;30:1-5.
95. Masson E, Lebel M. Céphalosporines orales. In: Bryskier A, editor. Antibiotiques, agents antibactériens et antifongiques. Paris: Ellipse édition; 1999. p. 286-304.
96. Masuda N, Gotoh N, Ishii C, Sakagawa E, Ohya S, Nishino T. Interplay between chromosomal β-lactamase and the MexAb-OprM efflux system in intrinsic resistance to β-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999;43:400-402.
97. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;44:3322-3327.
98. Mazzariol A, Cornaglia G, Nikaido H. Contribution of the Amp-C β-lactamase and the AcrAB multidrug efflux system in intrinsic resistance of E. coli K12 to β-lactams. Antimicrob Agents Chemother 2000;44:1387-1390.
99. Meideros AA. Cooperative evolution of mechanisms of β-lactam resistance. Clin Microbiol Infection 2000;6(suppl3):27S-33S.
100. Mendelmann PM, Chaffin D, Kalaizoglou G. Penicillin-binding proteins and ampicillin resistance in Haemophilus influenzae. J Antimicrob Chemother 1990;25:525-534.
101. Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol Infect Dis 1987;6:234-244.
102. Murray BE. β-lactamase-producing enterococci. Antimicrob Agents Chemother 1992;36:2355-2359.
103. Nagai K, Davies TA, Jacobs MR, Appelbaum PC. Effects of aminoacid alterations in penicillin-binding-proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, amoxicillin, cefditoren, cefuroxime, cefprozil and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate and resistant pneumococci. Antimicrob Agents Chemother 2002;46:1273-1280.
104. Neu HC. β-lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties. Rev Inf Dis 1986;8(suppl3):237S- 259S.
105. Neuman N. Administration optimale des anti-infectieux. Anti-infectieux: règles pratiques d'utilisation optimale. Paris: Masson; 1992. p. 19-62.
106. Neurwirth C, Siebor E, Duez JM, Pechinot A, Kazmierczak A. Imipenem resistance of Proteus mirabilis associated with alteration in penicillin-binding proteins. J Antimicrob Chemother 1995;36:335-342.
107. Nikaido H. Antibiotic resistance caused by Gram-negative multidrug efflux pumps. Clin Infect Dis 1998;27(suppl1):32S-41S.
108. Nikaido H. Crossing the enveloppe: how cephalosporins reach their targets. Clin Microbiol Infect 2000;6(suppl3):22S-26S.
109. Nikaido H, Basina M, Nguyen V, Rosenberg EY. Multidrug efflux pumps AcrAB of Salmonella typhimurium excretes only those β-lactam antibiotics containing lipophilic side chains. J Bacteriol 1998;180:4686-4692.
110. Nikaido H, Vaara M. Molecular basis of bacterial outer membrane permeability. Microbiol Rev 1985;49:1-32.
111. Nordmann P. Trends in β-lactam resistance among Enterobacteriaceae. Clin Infect Dis 1998;27(suppl1):100S-106S.
112. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002;8:321-331.
113. Oppenheim BA. Antibiotic resistance in Neisseria meningitidis. Clin Infect Dis 1997;24(suppl1):S98-S101.
114. Pangon B, Pina P, Gazagne L, Chauvel M, Godard T, Courvalin P, et al. Antimicrobial susceptibility of 471 enterococal strains responsible for infections at 101 french hospitals. Eur J Clin Microbiol Infect Dis 1999;18:836-838.
115. Petitjean O, Rosset MA. Aztréonam. Pharmacologie clinique. Paris: Expansion Scientifique Française; 1988. p. 1393-1397.
116. Petroni A, Corso A, Melano R, Cacace ML, Bru AM, Rossi A, Galas M. Plasmidic extended-spectrum β-lactamase in Vibrio cholerae O1 El Tor isolates in Argentina. Antimicrob Agents Chemother 2002;46:1462-1468.
117. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 2002;46:1-11.
118. Philippon A, Bernier M. Antibiotiques et bacilles à Gram négatif non fermentaires autres que Pseudomonas aeruginosa. In: Freney J, Renaud F, Hansen W, Bollet C, editors. Précis de bactériologie clinique. Paris: Éditions ESKA-Alexandre Lacassagne; 2000. p. 688-705.
119. Poirel L, Kämpfer P, Nordmann P. Chromosome-encoded Ambler class A β-lactamase of Kluyvera georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum β-lactamases. Antimicrob Agents Chemother 2002;46:4038-4040.
120. Quinn JP, Di Vicenzo CA, Lucks DA, Luskin RL, Shatzer KL, Lerner SA. Serious infections due to penicillin-resistant strains of viridans streptococci with altered penicillin-binding-proteins. J Infect Dis 1988;157:764-769.
121. Reichmann P, König A, Linares J, Alcaide F, Tenover F, McDougal L, et al. A global gene pool for high-level cephalosporin resistance in commensal Streptococcus species and Streptococcus pneumoniae. J Infect Dis 1997;176:1001-1012.
122. Rolinson N. β-lactam antibiotics. J Antimicrob Chemother 1986;17:5-36.
123. Rybkine T, Mainardi JL, Sougakoff W, Collatz E, Gutmann L. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of β-lactam resistance. J Infect Dis 1998;178:159-163.
124. Sader HS, Jones RN. Historical overview of the cephalosporin spectrum: four generations of structural evolution. Antimicrobic Newsletter 1992;8:75-84.
125. Sanders ML, Sanders WE. Typel β-lactamases of Gram-negative bacteria: interactions with β-lactam antibiotics. J Infect Dis 1986;154:792-800.
126. Schrag SJ, Beall B, Dowell SF. Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions. Clin Microbiol Rev 2000;13:588-601.
127. Sirot J, Nicolas-Chanoine MH, Chardon H, Avril JL, Cattoen C, Croix JC, et al. Susceptibility of Enterobacteriaceae to β-lactam agents and fluoroquinolone: a 3-year survey in France. Clin Microbiol Infect 2002;8:207-213.
128. Smith AM, Botha RF, Koornhof HJ, Klugman KP. Emergence of a pneumococcal clone with cephalosporin resistance and penicillin susceptibility. Antimicrob Agents Chemother 2001;45:2648-2650.
129. Smith JW, Piercy A. Infectious arthritis. Clin Infect Dis 1995;20:225-231.
130. Société de pathologie infectieuse de langue française. Deuxième conférence de consensus en thérapeutique antiinfectieuse: antibiothérapie des infections urinaires 16 novembre 1990. Méd Mal Infect 1991;12:59-62.
131. Société de pathologie infectieuse de langue française. Conférence de consensus en thérapeutique: les infections bactériennes en dehors des infections à mycobactéries, Tours, 25 janvier 1991. Méd Mal Infect 1991;21:453-457.
132. Société de pathologie infectieuse de langue française. Conférences de consensus. Les méningites purulentes communautaires. Méd Mal Infect 1996;26:952-973.
133. Société de pathologie infectieuse de langue française. Conférence de consensus.Érysipèle et fasciite nécrosante: prise en charge. Méd Mal Infect 2000;31(suppl4):252S-272S.
134. Société de pathologie infectieuse de langue française. Quelle doit être l'antibiothérapie de première intention des pneumonies aiguës communautaires? Quelle doit être sa réévaluation en cas d'échec, compte tenu de l'évolution des agents responsables, des résistances du pneumocoque et cela justifie-t-il des associations? Méd Mal Infect 2001;31:344-351.
135. Société de pathologie infectieuse de langue française. Prophylaxie de l'endocardite infectieuse. Révision de la conférence de consensus de mars 1992. Méd Mal Infect 2002;32:588-595.
136. Société française d'anesthésie réanimation. Conférences de consensus. Prise en charge des péritonites communautaires. Ann Fr Anesth Réanim 2001;20(suppl2):350-367.
137. Société nationale de gastroentérologie. Conférence de consensus. Maladie ulcéreuse et gastrites à l'heure de Helicobacter pylori. Lettre Infect 1996;11(suppl5):45-47.
138. Soussy CJ. Antibiotiques, généralités. In: Freney J, Renaud F, Hansen W, Boillet C, editors. Précis de bactériologie clinique. Paris: ESKA-Alexandre Lacassagne; 2000. p. 557-569.
139. Spratt BG. Hybrid penicillin binding proteins in penicillin-resistant strains of Neisseria gonorrhoeae. Nature 1988;332:173-176.
140. Tankovic J. Mécanismes d'action des antibiotiques. In: Freney J, Renaud F, Hansen W, Boillet C, editors. Précis de bactériologie clinique. Paris: ESKA-Alexandre Lacassagne; 2000. p. 583-595.
141. Tomasz A, Drugeon HB, De Lencastre HM, Javes D, Mac Dougall L, Bille J. New mechanism for methicillin résistant in Staphylococcus aureus: clinical isolates that lack the PLP2a gene and countain normal penicillin-binding capacity. Antimicrob Agents Chemother 1989;33:1869-1874.
142. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22.
143. Ubutaka K, Shibasaki Y, Yamamoto K, Chiba N, Hasegawa K, Takeuchi Y, et al. Association of amino acid substitutions in penicillin-binding protein 3 with β-lactam resistance in β-lactamase negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother 2001;45:1693-1699.
144. Veal WL, Nicholas RA, Shafer WM. Overexpression of the MtrC-MtrD-MtrE efflux pump due to a mtrR mutation is required for chromosally mediated penicillin resistance in Neisseria gonorrhoeae. J Bacteriol 2002;184:5619-5624.
145. Vergnaud M, Bourdon S, Brun M, et al. Observatoires du pneumocoque: analyse de la résistance aux antibiotiques et des sérotypes de Streptococcus pneumoniae en 2001. Bull Epidémiol Hebd 2003;37:173-176.
146. Vidal®. Le dictionnaire. Paris: Éditions du Vidal®; 2003.
147. Vidal®. Interactions médicamenteuses. Paris: Éditions du Vidal®; 2003.
148. Wielders CL, Fluit AC, Brisse S, Verhoef J, Schmitz FJ. mecA gene is widely disseminated in Staphylococcus aureus populations. J Clin Microbiol 2002;40:3970-3975.
149. Wolff M. Céphalosporines injectables. In: Carbon C, Régnier B, Saimot G, Vildé JL, Yeni P, editors. Médicaments anti-infectieux. (Paris 1994). Paris: Flammarion Médecine-Sciences; 1994. p. 74-85.